Nothing Special   »   [go: up one dir, main page]

NL1028192A1 - Gesubstitueerde chinolineverbindingen. - Google Patents

Gesubstitueerde chinolineverbindingen.

Info

Publication number
NL1028192A1
NL1028192A1 NL1028192A NL1028192A NL1028192A1 NL 1028192 A1 NL1028192 A1 NL 1028192A1 NL 1028192 A NL1028192 A NL 1028192A NL 1028192 A NL1028192 A NL 1028192A NL 1028192 A1 NL1028192 A1 NL 1028192A1
Authority
NL
Netherlands
Prior art keywords
substituted quinoline
quinoline compounds
compounds
substituted
quinoline
Prior art date
Application number
NL1028192A
Other languages
English (en)
Other versions
NL1028192C2 (nl
Inventor
Peter Bertinato
Michel Andre Couturier
Ernest Seiichi Hamanaka
Marcus Douglas Ewing
Ralph Pelton Robinson Jr
Derek Lawrence Tickner
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NL1028192A1 publication Critical patent/NL1028192A1/nl
Application granted granted Critical
Publication of NL1028192C2 publication Critical patent/NL1028192C2/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
NL1028192A 2004-02-04 2005-02-04 Gesubstitueerde chinolineverbindingen. NL1028192C2 (nl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US54167804P 2004-02-04 2004-02-04
US54167804 2004-02-04
US63376304P 2004-12-06 2004-12-06
US63376304 2004-12-06

Publications (2)

Publication Number Publication Date
NL1028192A1 true NL1028192A1 (nl) 2005-08-08
NL1028192C2 NL1028192C2 (nl) 2006-05-30

Family

ID=34890449

Family Applications (1)

Application Number Title Priority Date Filing Date
NL1028192A NL1028192C2 (nl) 2004-02-04 2005-02-04 Gesubstitueerde chinolineverbindingen.

Country Status (25)

Country Link
US (3) US7468378B2 (nl)
EP (1) EP1716137A1 (nl)
JP (1) JP2007520543A (nl)
KR (1) KR100799802B1 (nl)
AP (1) AP2006003685A0 (nl)
AR (1) AR047529A1 (nl)
AU (1) AU2005214159A1 (nl)
BR (1) BRPI0507462A (nl)
CA (1) CA2555133A1 (nl)
CO (1) CO5700721A2 (nl)
CR (1) CR8544A (nl)
EA (1) EA010369B1 (nl)
EC (1) ECSP066717A (nl)
GE (1) GEP20084360B (nl)
IL (2) IL176715A0 (nl)
MA (1) MA28347A1 (nl)
NL (1) NL1028192C2 (nl)
NO (1) NO20063928L (nl)
OA (1) OA13365A (nl)
PA (1) PA8623001A1 (nl)
PE (1) PE20050773A1 (nl)
SV (1) SV2007002007A (nl)
TW (2) TWI306454B (nl)
UY (1) UY28734A1 (nl)
WO (1) WO2005080373A1 (nl)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005044817A1 (en) 2003-11-05 2005-05-19 Sunesis Pharmaceuticals, Inc. Modulators of cellular adhesion
EP1716137A1 (en) * 2004-02-04 2006-11-02 Pfizer Products Incorporated Substituted quinoline compounds
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
JP2007532638A (ja) * 2004-04-14 2007-11-15 アストラゼネカ・アクチエボラーグ Ｎｋ１アンタゴニスト及びセロトニン再取り込み阻害剤としてのアリールグリシンアミド誘導体及びその使用
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
GEP20104878B (en) 2005-04-19 2010-01-11 Surface Logix Inc Inhibitors of microsomal triglyceride transfer protein and apo-b secretion
US8158650B2 (en) * 2006-10-23 2012-04-17 Pfizer Inc. Substituted phenylmethyl bicyclocarboxyamide compounds
AU2007320906A1 (en) 2006-11-13 2008-05-22 Pfizer Products Inc. Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof
EP2115368A1 (en) * 2007-02-02 2009-11-11 Steve D. Shivvers High efficiency drier with multi stage heating and drying zones
US20080249130A1 (en) * 2007-02-09 2008-10-09 Sirtris Pharmaceuticals, Inc. Gut microsomal triglyceride transport protein inhibitors
WO2009014674A1 (en) * 2007-07-23 2009-01-29 Sirtris Pharmaceuticals, Inc. Heterocyclylamides as gut microsomal triglyceride transport protein inhibitors
CA2702577A1 (en) 2007-10-15 2009-04-23 Jbs United, Inc. Method for increasing performance of offspring
ES2830024T3 (es) * 2007-10-19 2021-06-02 Novartis Ag Composiciones y métodos para el tratamiento del edema macular
WO2010018547A1 (en) * 2008-08-13 2010-02-18 Pfizer Inc. Aminoquinoline compounds
MY157429A (en) 2011-06-24 2016-06-15 Amgen Inc Trpm8 antagonists and their use in treatments
US8778941B2 (en) 2011-06-24 2014-07-15 Amgen Inc. TRPM8 antagonists and their use in treatments
RU2014108140A (ru) * 2011-08-04 2015-09-10 Эррэй Биофарма Инк. Соединение на основе хинозолина в качестве ингибиторов серен-треониновых киназ
US8952009B2 (en) 2012-08-06 2015-02-10 Amgen Inc. Chroman derivatives as TRPM8 inhibitors
EP3107540A4 (en) * 2014-02-17 2017-08-30 Hetero Research Foundation Polymorphs of lomitapide and its salts
CN112279808B (zh) 2014-10-06 2024-03-08 弗特克斯药品有限公司 囊性纤维化跨膜转导调节因子调节剂
WO2016055934A1 (en) * 2014-10-09 2016-04-14 Glenmark Pharmaceuticals Limited Amorphous form of lomitapide mesylate
PL3436446T3 (pl) 2016-03-31 2023-09-11 Vertex Pharmaceuticals Incorporated Modulatory mukowiscydozowego przezbłonowego regulatora przewodnictwa
PT3519401T (pt) 2016-09-30 2021-12-27 Vertex Pharma Modulador de regulador de condutância transmembranar de fibrose quística, composições farmacêuticas, métodos de tratamento e processo para fazer o modulador
MX2021013639A (es) 2016-12-09 2022-09-30 Vertex Pharma Forma cristalina del compuesto 1, un modulador del regulador de conductancia transmembrana de fibrosis quística, procesos para su preparación, composiciones farmacéuticas del compuesto 1, y su uso en el tratamiento de fibrosis quística.
BR112019025801A2 (pt) 2017-06-08 2020-07-07 Vertex Pharmaceuticals Incorporated métodos de tratamento para fibrose cística
EP3640242B1 (en) * 2017-06-16 2023-04-19 Hitgen Ltd. Rock-inhibiting compound and uses thereof
AU2018304168B2 (en) 2017-07-17 2023-05-04 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
JP7121794B2 (ja) 2017-08-02 2022-08-18 バーテックス ファーマシューティカルズ インコーポレイテッド ピロリジン化合物を調製するためのプロセス
TWI719349B (zh) 2017-10-19 2021-02-21 美商維泰克斯製藥公司 Ｃｆｔｒ調節劑之結晶形式及組合物
WO2019113476A2 (en) 2017-12-08 2019-06-13 Vertex Pharmaceuticals Incorporated Processes for making modulators of cystic fibrosis transmembrane conductance regulator
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
WO2019200246A1 (en) 2018-04-13 2019-10-17 Alexander Russell Abela Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2819039A1 (de) 1978-04-29 1979-11-08 Bayer Ag Leimungsmittel fuer papier
DK104382A (da) 1981-03-11 1982-09-12 Wellcome Found Fremgangsmaade til fremstilling af substituerede biphenylforbindelser
ES2111065T5 (es) 1991-04-16 2005-06-16 Nippon Shinyaku Company, Limited Procedimiento para producir una dispersion solida.
US5595872A (en) 1992-03-06 1997-01-21 Bristol-Myers Squibb Company Nucleic acids encoding microsomal trigyceride transfer protein
HU218419B (hu) 1992-03-06 2000-08-28 E.R. Squibb And Sons, Inc. Mikroszomális triglicerid transzfer protein (MTP) nagy molekulatömegű alegységének rekombináns úton történő előállítására és a protein és inhibitorainak kimutatására szolgáló eljárások
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
CZ291476B6 (cs) 1994-05-27 2003-03-12 Smithkline Beecham S. P. A. N-(alfa-Ethylbenzyl)-3-hydroxy-2-fenylchinolin-4-karboxamid, farmaceutický prostředek s jeho obsahem a použití
DE19504832A1 (de) 1995-02-14 1996-08-22 Basf Ag Feste Wirkstoff-Zubereitungen
DE19519245C2 (de) * 1995-04-14 2003-04-30 Boehringer Ingelheim Kg Neue Arylglycinamidderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
DE69529849T2 (de) 1995-06-07 2003-09-04 Pfizer Inc., New York Biphenyl-2-carbonsäure-tetrahydro-isochinolin-6-yl amid derivate, deren hestellung und deren verwendung als inhibitoren des mikrosomalen triglycerid-transfer-proteins und/oder der apolipoprotein b (apo b) sekretion
WO1996040640A1 (en) 1995-06-07 1996-12-19 Pfizer Inc. BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION
US5827875A (en) 1996-05-10 1998-10-27 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
PL329922A1 (en) * 1996-05-20 1999-04-26 Darwin Discovery Ltd Quinoline carboxamides as inhibitors of the tumour necrosis factor and of phosphodiesterase
AU3513497A (en) 1996-07-01 1998-01-21 Eli Lilly And Company Hypoglycemic and hypolipidemic compounds
KR100217618B1 (ko) * 1996-12-12 1999-09-01 정몽규 와셔액 분사위치 조절 장치
WO1998027979A1 (en) 1996-12-20 1998-07-02 Bristol-Myers Squibb Company Heterocyclic inhibitors of microsomal triglyceride transfer protein and method
US6066653A (en) 1997-01-17 2000-05-23 Bristol-Myers Squibb Co. Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs
US5968950A (en) 1997-06-23 1999-10-19 Pfizer Inc Apo B-secretion/MTP inhibitor hydrochloride salt
PT901786E (pt) 1997-08-11 2007-08-07 Pfizer Prod Inc Disperções farmacêuticas sólidas com biodisponibilidade melhorada
AP1201A (en) 1997-09-17 2003-09-01 Smithkline Beecham Corp Method for the synthesis of quinoline derivatives.
CA2309882A1 (en) * 1997-12-22 1999-07-01 Pharmacia & Upjohn Company 4-hydroxyquinoline-3-carboxamides and hydrazides as antiviral agents
CO5090829A1 (es) 1998-07-21 2001-10-30 Novartis Ag Compuestos organicos de la formula i, utiles como inhibido res de la proteina de transferencia de triglicerido microso mal y de la secrecion de la apolipoproteina b.
CA2325358C (en) * 1999-11-10 2005-08-02 Pfizer Products Inc. 7-¬(4'-trifluoromethyl-biphenyl-2-carbonyl)amino|-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein b
CO5271688A1 (es) 1999-11-10 2003-04-30 Pfizer Prod Inc Uso de inhibidor de secrecion de apoliproteinas b y/o de proteina de transferencia de trigliceridos microsmales
US20020032238A1 (en) * 2000-07-08 2002-03-14 Henning Priepke Biphenylcarboxylic acid amides, the preparation thereof and the use thereof as medicaments
US6417367B1 (en) * 2000-08-11 2002-07-09 Pfizer Inc. Methods of making quinoline amides
US20040058903A1 (en) 2000-10-05 2004-03-25 Hisashi Takasugi Benzamide compounds as apo b secretion inhibitors
WO2003002533A1 (en) 2001-06-28 2003-01-09 Pfizer Products Inc. Triamide-substituted indoles, benzofuranes and benzothiophenes as inhibitors of microsomal triglyceride transfer protein (mtp) and/or apolipoprotein b (apo b) secretion
HUP0700124A2 (en) * 2001-10-25 2007-06-28 Takeda Chemical Industries Ltd Quinoline compound
US20030162758A1 (en) * 2001-12-07 2003-08-28 Schwartz Daniel M. Treatment for age-related macular degeneration (AMD)
US20030162788A1 (en) * 2002-01-10 2003-08-28 Boehringer Ingelheim Pharma Kg Combination of MTP inhibitors or apoB-secretion inhibitors with fibrates for use as pharmaceuticals
RU2293721C2 (ru) 2002-02-28 2007-02-20 Джапан Тобакко Инк. Сложноэфирные соединения и их применение в медицине
WO2004056775A1 (en) * 2002-12-20 2004-07-08 Pfizer Products Inc. Microsomal triglyceride transfer protein inhibitors
AU2003286311A1 (en) * 2002-12-20 2004-07-14 Pfizer Products Inc. Microsomal triglyceride transfer protein inhibitors
EP1716137A1 (en) * 2004-02-04 2006-11-02 Pfizer Products Incorporated Substituted quinoline compounds

Also Published As

Publication number Publication date
EA200601239A1 (ru) 2007-02-27
MA28347A1 (fr) 2006-12-01
AP2006003685A0 (en) 2006-08-31
IL176715A0 (en) 2006-10-31
EP1716137A1 (en) 2006-11-02
JP2007520543A (ja) 2007-07-26
SV2007002007A (es) 2007-03-20
KR100799802B1 (ko) 2008-01-31
ECSP066717A (es) 2006-10-31
TW200533354A (en) 2005-10-16
CA2555133A1 (en) 2005-09-01
PA8623001A1 (es) 2006-03-24
US20070093525A1 (en) 2007-04-26
NO20063928L (no) 2006-10-31
CO5700721A2 (es) 2006-11-30
AR047529A1 (es) 2006-01-25
OA13365A (en) 2007-04-13
NL1028192C2 (nl) 2006-05-30
US7368573B2 (en) 2008-05-06
US20060223851A1 (en) 2006-10-05
TWI306454B (en) 2009-02-21
IL208963A0 (en) 2011-07-31
CR8544A (es) 2006-11-30
US20050234099A1 (en) 2005-10-20
WO2005080373A1 (en) 2005-09-01
BRPI0507462A (pt) 2007-07-10
TW200906800A (en) 2009-02-16
UY28734A1 (es) 2005-09-30
GEP20084360B (en) 2008-04-29
KR20060127123A (ko) 2006-12-11
AU2005214159A1 (en) 2005-09-01
PE20050773A1 (es) 2005-10-26
EA010369B1 (ru) 2008-08-29
US7468378B2 (en) 2008-12-23
US7393958B2 (en) 2008-07-01

Similar Documents

Publication Publication Date Title
NL1028192A1 (nl) Gesubstitueerde chinolineverbindingen.
NL1030863A1 (nl) Heteroaromatische chinolineverbindingen.
ATE477257T1 (de) Piperidinylamino-thienoä2,3-dü- pyrimidinverbindungen
NL1031385A1 (nl) Gesubstitueerde sulfonylaminoarylmethylcyclopropaancarbonamideverbindingen.
NL1028967A1 (nl) 4-Fenylamino-chinazoline-6-yl-amiden.
NO20051522D0 (no) Kabelskjotbeskytter.
NL1030382A1 (nl) Gesubstitueerde N-sulfonylaminobenzyl-2-fenoxyaceetamide verbindingen.
NO20053161D0 (no) Mikrobedrepende sammensetning.
NO20053210D0 (no) Linneslakkompensator.
NL1031335A1 (nl) Gesubstitueerde N-sulfonylaminofenylethyl-2-fenoxyaceetamideverbindingen.
NO20052746D0 (no) Avlopsenhet.
NO20041374L (no) Bolgekraftverk.
NL1030010A1 (nl) 4-Amino-gesubstitueerde-2-gesubstitueerde-1,2,3,4- tetrahydrochinolineverbindingen.
NO20052482D0 (no) Redningskokong.
NL1030012A1 (nl) Chinolineverbindingen.
NO20040762D0 (no) Stromskinne.
NL1028622A1 (nl) Stelwig.
ATE384719T1 (de) Dioxazinyl-substituierte thienylsulfonylaminocarbonylverbindungen
NL1029719A1 (nl) Ophaalgordijn.
SE0402103D0 (sv) Novel compounds
NL1025196A1 (nl) Hark-Zeef-Vork.
ES1057865Y (es) Desatascador de desagues.
ES1056921Y (es) Cinta flocada.
ES1059938Y (es) Paleta batefuegos escalonada.
ES1058195Y (es) Expositor -botellero.

Legal Events

Date Code Title Description
AD1A A request for search or an international type search has been filed
RD2N Patents in respect of which a decision has been taken or a report has been made (novelty report)

Effective date: 20060113

PD2B A search report has been drawn up
V1 Lapsed because of non-payment of the annual fee

Effective date: 20120901